Adrian Rawcliffe - Adaptimmune Therapeutics Principal CEO
| ADAP Stock | USD 0.84 0.03 3.45% |
CEO
Mr. Adrian Rawcliffe is appointed as Chief Executive Officer, Director of the company., effective September 1, 2019. He leads our financial strategy, management and operations functions including compliance and risk management. He has 17 years of experience within the pharmaceutical industry and most recently served as Senior Vice President, Finance of GSK North American Pharmaceuticals business. Mr. Rawcliffe joined GSK in 1998 and his other senior roles at the company included Senior Vice President Worldwide Business Development and RD Finance, where he was responsible for all business development and finance activities for GSK Pharmaceuticals RD business and Managing Partner and President of SR One Ltd, GSK venturecapital business. Mr. Rawcliffe qualified as a chartered accountant with PricewaterhouseCoopers and holds a B.Sc. degree in Natural Sciences from the University of Durham, UK. since 2015.
| Age | 52 |
| Tenure | 9 years |
| Address | 60 Jubilee Avenue, Abingdon, United Kingdom, OX14 4RX |
| Phone | 44 12 3543 0000 |
| Web | https://www.adaptimmune.com |
Adrian Rawcliffe Latest Insider Activity
Tracking and analyzing the buying and selling activities of Adrian Rawcliffe against Adaptimmune Therapeutics stock is an integral part of due diligence when investing in Adaptimmune Therapeutics. Adrian Rawcliffe insider activity provides valuable insight into whether Adaptimmune Therapeutics is net buyers or sellers over its current business cycle. Note, Adaptimmune Therapeutics insiders must abide by specific rules, including filing SEC forms every time they buy or sell Adaptimmune Therapeutics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Adrian Rawcliffe over six months ago Acquisition by Adrian Rawcliffe of 45000 shares of Wave Life at 4.58 subject to Rule 16b-3 |
Adaptimmune Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.1584) % which means that it has lost $0.1584 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6504) %, meaning that it created substantial loss on money invested by shareholders. Adaptimmune Therapeutics' management efficiency ratios could be used to measure how well Adaptimmune Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of 10/19/2024, Return On Tangible Assets is likely to drop to -0.43. In addition to that, Return On Capital Employed is likely to drop to -0.69. As of 10/19/2024, Non Current Liabilities Total is likely to grow to about 178.8 M, while Total Current Liabilities is likely to drop slightly above 44.6 M.Similar Executives
| Found 6 records | CEO Age | ||
| Frank BeduAddo | PDS Biotechnology Corp | 59 | |
| Paul Hastings | Nkarta Inc | 64 | |
| Adi Hoess | Affimed NV | 63 | |
| Stephen JD | Pieris Pharmaceuticals | 48 | |
| Jennifer Buell | Mink Therapeutics | 49 | |
| Denise ScotsKnight | Mereo BioPharma Group | 65 | |
Management Performance
| Return On Equity | -0.65 | ||||
| Return On Asset | -0.16 |
Adaptimmune Therapeutics Leadership Team
Elected by the shareholders, the Adaptimmune Therapeutics' board of directors comprises two types of representatives: Adaptimmune Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Adaptimmune. The board's role is to monitor Adaptimmune Therapeutics' management team and ensure that shareholders' interests are well served. Adaptimmune Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Adaptimmune Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Kerry Sharp, Senior Council | ||
| Dennis Williams, Senior Development | ||
| Sbastien Desprez, VP Affairs | ||
| Dana Lynch, Senior Communications | ||
| Helen MBA, CoFounder Officer | ||
| Bertrand Esq, Chief Officer | ||
| Adrian Rawcliffe, Principal CEO | ||
| Juli Miller, VP Relations | ||
| Margaret Henry, Head Sec | ||
| MD BA, Chief Officer | ||
| Cintia PharmD, Chief Officer | ||
| ACA BA, Chief Officer | ||
| John Lunger, Chief Patient Supply Officer | ||
| BA ACA, Chief Officer | ||
| Joanna Brewer, Chief Officer |
Adaptimmune Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Adaptimmune Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.65 | ||||
| Return On Asset | -0.16 | ||||
| Profit Margin | (0.51) % | ||||
| Operating Margin | 0.54 % | ||||
| Current Valuation | 47.77 M | ||||
| Shares Outstanding | 255.74 M | ||||
| Shares Owned By Insiders | 0.37 % | ||||
| Shares Owned By Institutions | 61.20 % | ||||
| Number Of Shares Shorted | 6.09 M | ||||
| Price To Earning | (7.73) X |
Pair Trading with Adaptimmune Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Adaptimmune Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Adaptimmune Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Adaptimmune Stock
| 0.77 | VALN | Valneva SE ADR | PairCorr |
| 0.83 | DYAI | Dyadic International | PairCorr |
| 0.83 | ERNA | Eterna Therapeutics | PairCorr |
Moving against Adaptimmune Stock
| 0.71 | GNFT | Genfit | PairCorr |
| 0.66 | GILD | Gilead Sciences | PairCorr |
| 0.63 | BMY | Bristol Myers Squibb | PairCorr |
| 0.58 | WVE | Wave Life Sciences | PairCorr |
| 0.41 | A | Agilent Technologies Fiscal Year End 18th of November 2024 | PairCorr |
The ability to find closely correlated positions to Adaptimmune Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Adaptimmune Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Adaptimmune Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Adaptimmune Therapeutics Plc to buy it.
The correlation of Adaptimmune Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Adaptimmune Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Adaptimmune Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Adaptimmune Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Adaptimmune Stock Analysis
When running Adaptimmune Therapeutics' price analysis, check to measure Adaptimmune Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adaptimmune Therapeutics is operating at the current time. Most of Adaptimmune Therapeutics' value examination focuses on studying past and present price action to predict the probability of Adaptimmune Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Adaptimmune Therapeutics' price. Additionally, you may evaluate how the addition of Adaptimmune Therapeutics to your portfolios can decrease your overall portfolio volatility.